UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 13G
Under the Securities Exchange Act of 1934
SciClone Pharmaceuticals, Inc.
------------------------------
(Name of Issuer)
Common Stock, no par value
------------------------------
(Title of Class of Securities)
80862K104
--------------
(CUSIP Number)
December 15, 1998
-------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
( ) Rule 13d-1(b)
(x) Rule 13d-1(c)
( ) Rule 13d-1(d)
* The remainder of this cover page shall be filled out for a reporting person's
initial filing on this form with respect to the subject class of securities, and
for any subsequent amendment containing information which would alter the
disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed
to be "filed" for the purpose of Section 18 of the Securities Exchange Act of
1934 ("Act") or otherwise subject to the liabilities of that section of the Act
but shall be subject to all other provisions of the Act.
(Page 1 of 6 Pages)
<PAGE>
CUSIP No. 80862K104 13G Page 2 of 6 Pages
- --------------------------------------------------------------------------------
1) NAME OF REPORTING PERSON
Halifax Fund, L.P.
- --------------------------------------------------------------------------------
2) CHECK THE APPROPRIATE BOX IF MEMBER OF A GROUP
(a) [ ]
(b) [ ]
- --------------------------------------------------------------------------------
3) SEC USE ONLY
- --------------------------------------------------------------------------------
4) CITIZENSHIP OR PLACE OF ORGANIZATION
Cayman Islands
- --------------------------------------------------------------------------------
5) SOLE VOTING POWER
2,137,068
NUMBER OF ------------------------------------------------------------------
SHARES 6) SHARED VOTING POWER
BENEFICIALLY 0
OWNED BY ------------------------------------------------------------------
EACH 7) SOLE DISPOSITIVE POWER
REPORTING 2,137,068
PERSON WITH ------------------------------------------------------------------
8) SHARED DISPOSITIVE POWER
0
- --------------------------------------------------------------------------------
9) AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,137,068
- --------------------------------------------------------------------------------
10) CHECK IF THE AGGREGATE AMOUNT IN ROW 11 EXCLUDES
CERTAIN SHARES [ ]
- --------------------------------------------------------------------------------
11) PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 11
9.9%
- --------------------------------------------------------------------------------
12) TYPE OF REPORTING PERSON:
OO
- --------------------------------------------------------------------------------
<PAGE>
Item 1(a). Name of Issuer:
- ---------- ---------------
SciClone Pharmaceuticals, Inc.
Item 1(b). Address of Issuer's Principal Executive Offices:
- ---------- ------------------------------------------------
901 Mariners Island Blvd
Suite 315
San Mateo, California 94404
Item 2(a). Name of Person Filing:
- ---------- ----------------------
Halifax Fund, L.P.
Item 2(b). Address of Principal Business Office:
- ---------- -------------------------------------
c/o The Palladin Group, L.P.
40 West 57th Street
15th Floor
New York, NY 10019
Item 2(c). Citizenship:
- ---------- ------------
Cayman Islands
Item 2(d). Title of Class of Securities:
- ---------- -----------------------------
Common Stock
Item 2(d). CUSIP Number:
- ---------- -------------
80862K104
Page 3 of 6 Pages
<PAGE>
If this statement is filed pursuant to Rule 13d-1(b) or
13d-2(b) or (c),
Item 3. check whether the person filing is a:
- ------- --------------------------------------------------------------
(a) [ ] Broker or dealer registered under Section 15 of the Exchange
Act.
(b) [ ] Bank as defined in Section 3(a)(6) of the Exchange Act.
(c) [ ] Insurance company as defined in Section 3(a)(19) of the
Exchange Act.
(d) [ ] Investment company registered under Section 8 of the
Investment Company Act.
(e) [ ] An investment advisor in accordance with
Rule 13d-1(b)(1)(ii)(E);
(f) [ ] An employee benefit plan or endowment fund in accordance with
Rule 13d-1(b)(1)(ii)(F);
(g) [ ] A parent holding company or control person in accordance with
Rule 13d-1(b)(1)(ii)(G);
(h) [ ] A savings association as defined in Section 3(b) of the
Federal Deposit Insurance Act;
(i) [ ] A church plan that is excluded form the definition of an
investment company under section 3(c)(14) of the Investment
Company Act;
(j) [ ] Group, in accordance with Rule 13d-1(b)1)(ii)(J).
Item 4. Ownership.
- ------- ---------
(a) Amount Beneficially Owned: 2,137,068
(b) Percent of Class: 9.9%
(c) Number of Shares to which such person has:
(i) Sole power to vote or direct
the vote: 2,137,068
(ii) Shared power to vote or direct
the vote: 0
(iii) Sole power to dispose or to direct
the deposition of: 2,137,068
(iv) Shared power to dispose or to
direct the disposition of: 0
Page 4 of 6 Pages
<PAGE>
Item 5. Ownership of Five Percent or Less of a Class.
- ------- ---------------------------------------------
If this statement is being filed to report the fact that as of the date
of the reporting person has ceased to be the beneficial owner of more than five
percent of the class of securities, check the following [ ].
Ownership of More than Five Percent on Behalf of
Item 6. Another Person
- ------- ------------------------------------------------
Not Applicable.
Identification and Classification of the
Subsidiary Which acquired the Security Being
Item 7. Reported on By the Parent Holding Company
- ------- --------------------------------------------
Not Applicable.
Identification and Classification of Members of
Item 8. the Group.
- ------- -----------------------------------------------
Not Applicable.
Item 9. Notice of Dissolution of the Group.
- ------- -----------------------------------
Not Applicable.
Page 5 of 6 Pages
<PAGE>
Item 10. Certification.
- -------- --------------
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
SIGNATURE
After reasonably inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
January 6, 1999
----------------------------------------
Date
Halifax Fund, L.P.
By: The Palladin Group, L.P.
Attorney-in-fact
By: Palladin Capital Management, L.L.C.
General Partner
/s/ Robert L. Chender
----------------------------------------
Signature
Robert L. Chender
Duly Authorized Signatory
----------------------------------------
Name/Title
Page 6 of 6 Pages
